Shares of AngioDynamics ( ANGO -4.24%) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came ...

AngioDynamics, Inc. ANGO reported an adjusted loss per share of 11 cents for first-quarter fiscal 2025, against the year-ago ...

Throughout the last three months, 4 analysts have evaluated AngioDynamics ANGO -7.14% Get Free Report , offering a diverse ...

AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on AngioDynamics (ANGO – Research Report) today and set a price target of $14.00.

For the year, the company backed its outlook for sales of between $282 million and $288 million and an adjusted loss between 42 cents a share and 38 cents a share. Analysts surveyed by FactSet are ...

For the full year, AngioDynamics expects net sales to be in the range of $282 to $288 million, and adjusted loss per share of between $0.38 and $0.42. Analysts expect the company to report a loss of ...

AngioDynamics swung to a loss in its fiscal first quarter, although better than feared, and said it continues to expect sales growth in fiscal 2025.

Q1 2025 Earnings Conference Call October 3, 2024 8:00 AM ETCompany ParticipantsJim Clemmer - President and Chief ...

AngioDynamics expects full-year earnings in the range of 38 cents to 42 cents per share, with revenue in the range of $282 million to $288 million. AngioDynamics shares have decreased slightly more ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc ...

Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC and Midline product portfolios divested in February 2024, as well as the discontinued Radiofrequency ...